Our findings demonstrate that DUX4-provoked toxicity is involved in the activation of the ferroptosis-related pathway and that supplementary iron could be a promising and readily available therapeutic option for FSHD. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.